Saurabh Zanwar (@zanwarsaurabh) ranks #15 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 20 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: CERVINO, anito-cel, TRIlogy-1. This profile quotes their 6 trial posts from 2026 word for word, with links to the originals on X.
At a Glance
- 6 posts naming a trial since ASH 2025
- 6 trials discussed by name
- Multiple Myeloma: US #15, Global #18 · 20 physicians engaged
- Leading physician voice: #2 of 6 physicians on MajesTEC-5; #3 of 7 physicians on anito-cel
- Presented at ASH 2025 in 2026
This Month
What Saurabh Zanwar has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
Who Amplifies Saurabh Zanwar
Physicians who reposted Saurabh Zanwar’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #15 | #18 | 55/100 | 20 | 28 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Saurabh Zanwar presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASH 2025 · PosterHigh-risk profiles and poor prognosis with bispecifics in RRMM: real-world analysis of 943 treatment initiations (abstract 4069)Source: Multiple Myeloma Hub ↗
Trials Saurabh Zanwar Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| CERVINO | 1 | #7 of 11 | Sep 25, 2026 |
| anito-cel | 1 | #3 of 7 | Sep 24, 2026 |
| TRIlogy-1 | 1 | #3 of 5 | Sep 24, 2026 |
| MajesTEC-3 | 1 | #14 of 15 | Sep 23, 2026 |
| MAIA | 1 | #3 of 5 | Aug 25, 2026 |
| MajesTEC-5 | 1 | #2 of 6 | Jun 28, 2026 |
Saurabh Zanwar on CERVINO
#IMS26 Plenary presentation for CERVINO demonstrates clear superiority of TCEs over SOC! 👏👏@PlasmaCellPete @myelomaMD et al. 12-mo PFS of 62.1% with Etentamig vs. 28.4% with control (Kd, SVd, EloPd) OS showing encouraging trend as well! Surely no more non TCE control arms https://t.co/uJfngfYOza
Saurabh Zanwar on anito-cel
Wonderful editorial by @YiLinMDPhD accompanying the promising phase I results of anito-cel on the heels of #IMS26 https://t.co/QK4bgUYWLJ Lack of binding to claudin-9 may spare the risk of IEC colitis noted with cilta-cel. Faster off rate due to the smaller synthetic ddBCMA
Saurabh Zanwar on TRIlogy-1
Phenomenal results with TRIlogy-1 presented at #IMS26 by @MileHighMyeloma 93% MRD neg at 10(-6), CR rates of 79%, VGPR rates ≥ 90% and 2-year PFS rates of 81.3%!! Favorable dosing schedule, skin/nail toxicities seem much more manageable than the GPRC5D and minimal treatment https://t.co/S9btK3kenP
Saurabh Zanwar on MajesTEC-3
It’s quite remarkable the numbers we are looking at in relapsed MM! These modeled data from the landmark MajesTEC-3 trial showing projected relative survival of >85% with Tec-Dara. While very provocative, followup is still short for longterm projections. Fingers crossed 🤞 https://t.co/zPPu1ED85X
Saurabh Zanwar on MAIA
Longterm follow up from MAIA shows absolutely phenomenal results for DRd! Median OS for the entire cohort of 90 months. Nearly 20% patients in the study were >80 years at enrollment, and the median OS in this subgroup was close to 70 months! Glad to see the exploratory https://t.co/rw6WvdBkfZ
Saurabh Zanwar on MajesTEC-5
GMMG-HD10/MajesTEC-5 represents an important and likely a watershed moment in myeloma induction and consolidation therapy! Amazing early and deep responses (100% MRD neg rates!!) 👏👏 @RascheLeo @RaabMarc et al. AntiCD38-based quadruplets set the bar pretty high for early PFS
Saurabh Zanwar’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Never a good time to be a myeloma patient but this is the best it has ever been! Remarkable results in early relapse setting! @mvmateos #IMS26 https://t.co/rNUviKkXc5